Triamterene
SIGMA/T4143 - ≥99%
Synonym: 2,4,7-
CAS Number: 396-01-0
Empirical Formula (Hill Notation): C12H11N7
Molecular Weight: 253.26
EC Number: 206-904-3
MDL Number: MFCD00006708
Linear Formula: C12H11N7
Product Type: Chemical
| assay | ≥99% |
| InChI | 1S/C12H11N7/c13-9-7(6-4-2 |
| InChI key | FNYLWPVRPXGIIP-UHFFFAOYSA |
| originator | Wellspring |
| Quality Level | 100 ![]() |
| SMILES string | Nc1nc(N)c2nc(-c3ccccc3)c( |
| solubility | 45% (w/v) aq 2-hydroxypropyl-β-cyclode |
| DMSO: soluble 5.4 mg/mL | |
| H2O: insoluble |
| Application: | Triamterene has been used to study its effects on urokinase receptor (uPAR) induction in podocytes under in vitro conditions2. Triamterene has also been identified as an activator compound from a LOPAC library screen using a fluorogenic α-glucosidase assay3. |
| Biochem/physiol Actions: | Weak diuretic with potassium sparing properties; blocks Na+ reuptake in the kidneys. |
| Features and Benefits: | This compound was developed by Wellspring . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Preparation Note: | 200 mg of triamterene is soluble in 4 ml of warm formic acid and yields a clear, yellow-green solution. Triamterene is also soluble in DMSO (5.4 mg/ml), and in 45% (w/v) aqueous 2-hydroxypropyl-β-cyclode |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 - H315 - H319 - H335 |
| Precautionary statements | P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26-36/37/39 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥99% |
| UNSPSC | 12352200 |


